Contribute Try STAT+ Today

Amid concerns over access to medicines that were hatched with U.S. taxpayer funds, Democratic lawmakers have asked the Government Accountability Office to investigate the discovery and development of remdesivir, which is the first drug authorized to treat Covid-19.

In a letter to the congressional watchdog, the lawmakers argue that the medicine, which is sold by Gilead Sciences (GILD), eventually reached patients thanks, in part, to an estimated $70 million in federal funding and ”key scientific contributions” from U.S. government scientists.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.